Syros Pharmaceuticals. has filed a patent for a method of treating malignancies, including tumors and cancers, by orally administering lyophilized compositions containing arsenic. The patent also covers the formulation and preparation of the oral pharmaceutical formulation. The method involves solubilizing arsenic trioxide powder, lyophilizing it, and optionally adding bulking agents and lubricants to generate the oral formulation. GlobalData’s report on Syros Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Syros Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Syros Pharmaceuticals's grant share as of September 2023 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Oral formulation of lyophilized arsenic for treating malignancies
A recently filed patent (Publication Number: US20230310325A1) describes a method for preparing an oral pharmaceutical formulation containing arsenic or lyophilized arsenic trioxide (As2O3). The method involves solubilizing As2O3 powder in an aqueous medium, followed by lyophilization to generate a lyopremix. The lyopremix is then sifted to obtain lyophilized As2O3 powder. Optionally, bulking agents and lubricants can be added to the lyophilized powder to create the final oral formulation of As2O3.
The patent also discloses a pharmaceutical composition in a solid dosage form suitable for oral administration. This composition consists of a lyophilized composition containing arsenic. The composition can be used for treating cancer in patients by administering a therapeutically effective amount of the pharmaceutical composition.
The pharmaceutical composition described in the patent includes specific proportions of lyophilized composition, bulking agent, and lubricant. The lyophilized composition and bulking agent make up about 98% of the composition by weight, while the lubricant constitutes about 2% by weight. The lyophilized composition comprises particles in the size range of 2 to 10 microns and has a BET surface area between 0.5 m2/g and 5 m2/g.
The patent also mentions the use of specific surfactants, such as sodium lauryl sulfate (SLS) or polysorbate 80, in the pharmaceutical composition. The amount of surfactant should not exceed 50% of the weight of arsenic trioxide.
The solid dosage form of the pharmaceutical composition can be a capsule or tablet, with a preference for capsules. The capsules can contain varying amounts of the lyophilized composition in powder form, ranging from 0.25 mg to 50 mg.
Additionally, the patent describes a kit that includes the pharmaceutical composition and instructions for use. The composition can be used to treat various types of cancer, including hematological malignancies like acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), lymphoma, and multiple myeloma (MM). Specifically, the composition is effective in treating acute promyelocytic leukemia (APL), both newly diagnosed and relapsed or refractory cases.
The method of administering the pharmaceutical composition can be once daily, with a dosage range of 1 mg to 50 mg or 0.1 mg/kg body weight to 0.3 mg/kg body weight. The patients may have previously undergone or currently be undergoing chemotherapy and/or radiation treatment.
In summary, the patent describes a method for preparing an oral pharmaceutical formulation containing lyophilized arsenic trioxide, as well as a solid dosage form of the composition for treating cancer, particularly hematological malignancies like AML and APL. The patent also includes details on the proportions of ingredients, surfactants, and administration methods.
To know more about GlobalData’s detailed insights on Syros Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
